Rapt Therapeutics Inc (RAPT) USD0.0001

Sell:$28.93Buy:$29.10$0.73 (2.58%)

Prices delayed by at least 15 minutes
Sell:$28.93
Buy:$29.10
Change:$0.73 (2.58%)
Deal now
Prices delayed by at least 15 minutes
Sell:$28.93
Buy:$29.10
Change:$0.73 (2.58%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.

Key people

Brian Wong
President, Chief Executive Officer, Director
Rodney K. B. Young
Chief Financial Officer
Dirk Brockstedt
Chief Scientific Officer
William Ho
Chief Medical Officer
Lori Lyons-Williams
Independent Chairman of the Board
Scott N. Braunstein
Independent Director
Ashley Dombkowski
Independent Director
Michael F. Giordano
Independent Director
Mary Ann Gray
Independent Director
Click to see more

Key facts

  • Shares in issue
    24.87m
  • EPIC
    RAPT
  • ISIN
    US75382E2081
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $708.78m
  • Employees
    61
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.